蘇智銘(Su, Chih-Ming) 副教授

Email
su08261@tmu.edu.tw
現   職
外科學科 副教授

學經歷

學 歷

畢業學校與學位[修業時間]
臺北醫學大學臨床醫學研究所 博士
2010/07~2015/06
臺北醫學院醫學系 學士
1993/07~2000/06

本校學術經歷

任職單位與職稱[起迄時間]
外科學科副教授
2023/02/01~
外科學科助理教授
2016/03/31~2023/01/31

本校兼職教學行政經歷

服務單位與職稱[起迄時間]
無資料!

其它經歷

任職單位與職稱[起迄時間]
雙和醫院主治醫師
臺北醫學大學附設醫院主治醫師
2007/08~2008/06
林口長庚醫院住院醫師
2002/07/01~2007/06/30

專長與研究領域

學門領域
學術專長

論文著作

清冊下載


1. 2023 Tung-Wei Hsu,Hsin-An Chen,Wan-Yu Wang,Yen-Hao Su,Ming-Te Huang,Po-Hsiang Liao. Chaperone-mediated autophagy degrade Dicer to promote breast cancer metastasis . Journal of Cellular Physiology .2023 ;(238):829-841

2. 2022 Chia-Hung Hsu,Hon-Ping Ma,Jiann Ruey Ong,Ming-Shou Hsieh. Cancer-associated exosomal CBFB facilitate the aggressive phenotype, evasion of oxidative stress, and preferential predisposition to bone prometastatic factor of breast cancer progression . Disease Markers .2022 ;(2022)

3. 2022 Tung-Wei Hsu,Hsin-An Chen,Po-Hsiang Liao,Yen-Hao Su,Ching-Feng Chiu,Shian-Ying Sung. Dicer-mediated miR-200b expression contributes to cell migratory/ invasive abilities and cancer stem cells properties of breast cancer cells . Aging .2022 ;(14)

4. 2022 Ruo-Kai Lin, Shih-Yun Lin,,Thi Anh Thu Le,Phui-Ly Liew,Cheng-Yang Lee,Chin-Sheng Hung. Hypermethylation of TMEM240 Predicts Poor Hormone Therapy Response and Disease Progression in Breast Cancer . Molecular Medicine .2022

5. 2022 Shi Qian Lin,Hsueh Chi Wu,Yun Yun Chou,Yu Chun Yen,Ka Wai Tam. Effect of patient decision aids on decisional conflict and regret associated with breast cancer surgery: a randomized controlled trial . Breast Cancer .2022 ;(29):880-888

6. 2021 Satriyo PB,Yeh CT. 4-Acetylantroquinonol B induced DNA damage response signaling and apoptosis via suppressing CDK2/CDK4 expression in triple negative breast cancer cells. . Toxicology and Applied Pharmacology .2021 ;(422):115-493

7. 2021 Su YH,Chen HA. AXL is crucial for E1A-enhanced therapeutic efficiency of EGFR tyrosine kinase inhibitors through NFI in breast cancer. . Environmental Toxicology .2021 ;(36):1278-1287

8. 2021 Lin RK. Automatic Detection of the Circulating Cell-Free Methylated DNA Pattern of GCM2, ITPRIPL1 and CCDC181 for Detection of Early Breast Cancer and Surgical Treatment Response. . Cancers .2021 ;(13):1375-1380

9. 2020 Su CM,Zhou JF,Chen HA. Cryptanshinone Inhibits the Glycolysis and Inhibits Cell Migration Through PKM2/β-Catenin Axis in Breast Cancer . Onco Targets and therapy .2020 ;(13):8629-8639

10. 2020 Su YH,Chen HA,Su CM,Huang MT. ERK-mediated transcriptional activation of Dicer is involved in gemcitabine resistance of pancreatic cancer . Jornal of cellular physiology .2020

11. 2019 Tam KW. Reply to correspondence concerning "Acupuncture on aromatase inhibitor-induced arthralgia in patients with breast cancer". . Breast .2019 ;(45):119-120

12. 2016 Chih-Ming Su,Ting-Yu Chang,Hui-Ping Hsu,Hui-Huang Lai,Jie-Ning Li,Yu-Jhen Lyu, Kuang-Tai Kuo, Ming-Te Huang, Jen-Liang Su, Pai-Sheng Chen. A novel application of E1A in combination therapy with EGFR- TKI treatment in breast cancer . Oncotarget .2016 ;(7):63924-63936

13. 2016 Tam KW. Recommendation for axillary lymph node dissection in women with early breast cancer and sentinel node metastasis: A systematic review and meta-analysis of randomized controlled trials using the GRADE system. . Int J Sur .2016 ;(34):73-80

14. 2015 Su CM. miR-520h is crucial for DAPK2 regulation and breast cancer progression. . Oncogene .2015 ;(35):1132-1142

15. 2015 Su CM. Pterostilbene inhibits triple-negative breast cancer metastasis via inducing microRNA-205 expression and negatively modulates epithelial-to-mesenchymal transition . .2015 ;(26):675-685

16. 2014 Su CM. Vascular endothelial growth factor-C upregulated contractin and promotes metastasis of esophageal squamous cell carcinoma. . Annal od Surgical Oncology .2014 ;(supp):767-775

17. 2014 Su CM. Novel peptides suppress VEGFR-3 activity and antagonize VEGFR-3-mediated oncogenic effects . Oncotarget .2014 ;(5):3825-3835

研究計畫

計畫名稱
106 研究合併E1A基因和表皮生長因子受體酪氨酸激?抑制劑在三重陰性乳癌臨床前治療的嶄新策略(3/3)
補助單位
科技部

計畫名稱
105 研究合併E1A基因和表皮生長因子受體酪氨酸激?抑制劑在三重陰性乳癌臨床前治療的嶄新策略(2/3)
補助單位
科技部

計畫名稱
105 研究合併E1A基因和表皮生長因子受體酪氨酸激?抑制劑在三重陰性乳癌臨床前治療的嶄新策略(2/3)
補助單位

計畫名稱
104 開發及臨床前評估鈣黏蛋白11單株抗體作為抗藥性及轉移性乳癌的治療策略
補助單位
行政院衛生署雙和醫院(委託臺北醫學大學興建經營)

計畫名稱
104 研究合併E1A基因和表皮生長因子受體酪氨酸激?抑制劑在三重陰性乳癌臨床前治療的嶄新策略(1/3)
補助單位
科技部

計畫名稱
104 研究合併E1A基因和表皮生長因子受體酪氨酸激酶抑制劑在三重陰性乳癌臨床前治療的嶄新策略(1/3)
補助單位
科技部